Deerfield Management Company, L.P. (Series C) Aeglea Bio Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$6.51 - $9.33 $5.37 Million - $7.7 Million
-825,000 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$4.01 - $11.04 $3.31 Million - $9.11 Million
825,000 New
825,000 $7.63 Million
Q4 2019

Feb 14, 2020
SELL
$7.23 - $8.55 $3.62 Million - $4.28 Million
-500,046 Closed
0 $0
Q1 2019

May 15, 2019
BUY
$7.6 - $9.4 $3.8 Million - $4.7 Million
500,046 New
500,046 $4.03 Million

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0
View Full List

About Aeglea BioTherapeutics, Inc.

AGLE Quotes by TradingView
  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email